No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System. Methods: A total of 279 H/VH risk MDS patients registered in the Korean MDS Working Party database were retrospectively analyzed. Results: HMA therapy was administered to 205 patients (73.5%), including 31 patients (11.1%) who then received allogeneic hematopoietic cell transplantation (allo- HCT), while 74 patients (26.5%) received BSC or allo-HCT without HMA. The 3-year overall survival (OS) rates were 53.1% ± 10.7% for allo-HCT with HMA, 75% ± 21.7% for allo-HCT without HMA, 17.3% ± 3.6% for HMA, and 20.8% ± 6.9% for BSC groups (p < 0.001). In the multivariate analysis, only allo-HCT was related with favorable OS (hazard ratio [HR], 0.356; p = 0.002), while very poor cytogenetic risk (HR, 5.696; p = 0.042), age ≥ 65 years (HR, 1.578; p = 0.022), Eastern Cooperative Oncology Group performance status (ECOG PS) 2 to 4 (HR, 2.837; p < 0.001), and transformation to acute myeloid leukemia (AML) (HR, 1.901; p = 0.001) all had an adverse effect on OS. Conclusions: For the H/VH risk group, very poor cytogenetic risk, age ≥ 65 years, ECOG PS 2 to 4, and AML transformation were poor prognostic factors. HMA showed no benefit in terms of OS when compared to BSC. Allo-HCT was the only factor predicting a favorable long-term outcome. The use of HMA therapy did not seem to have an adverse effect on the transplantation outcomes. However, the conclusion of this study should be carefully interpreted and proven by large scale research in the future.
Abstract
Background/Aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System. Methods: A total of 279 H/VH risk MDS patients registered in the Korean MDS Working Party database were retrospectively analyzed. Results: HMA therapy was administered to 205 patients (73.5%), including 31 patients (11.1%) who then received allogeneic hematopoietic cell transplantation (allo- HCT), while 74 patients (26.5%) received BSC or allo-HCT without HMA. The 3-year overall survival (OS) rates were 53.1% ± 10.7% for allo-HCT with HMA, 75% ± 21.7% for allo-HCT without HMA, 17.3% ± 3.6% for HMA, and 20.8% ± 6.9% for BSC groups (p < 0.001). In the multivariate analysis, only allo-HCT was related with favorable OS (hazard ratio [HR], 0.356; p = 0.002), while very poor cytogenetic risk (HR, 5.696; p = 0.042), age ≥ 65 years (HR, 1.578; p = 0.022), Eastern Cooperative Oncology Group performance status (ECOG PS) 2 to 4 (HR, 2.837; p < 0.001), and transformation to acute myeloid leukemia (AML) (HR, 1.901; p = 0.001) all had an adverse effect on OS. Conclusions: For the H/VH risk group, very poor cytogenetic risk, age ≥ 65 years, ECOG PS 2 to 4, and AML transformation were poor prognostic factors. HMA showed no benefit in terms of OS when compared to BSC. Allo-HCT was the only factor predicting a favorable long-term outcome. The use of HMA therapy did not seem to have an adverse effect on the transplantation outcomes. However, the conclusion of this study should be carefully interpreted and proven by large scale research in the future.
참고문헌 (24)
- Greenberg PL, "Myelodysplastic syndromes, version 2.2015", J Natl Compr Canc Netw, 13, pp.261~272 (2015)
- Oran B, "Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes", Clin Lymphoma Myeloma Leuk, 13(Suppl 2), pp.S282~S288 (2013)
- Sekeres MA, "The euphoria of hypomethylating agents in MDS and AML: is it justified?", Best Pract Res Clin Haematol, 26, pp.275~278 (2013)
- Steensma DP, "Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?", Best Pract Res Clin Haematol, 25, pp.443~451 (2012)
- Kim Y, "Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes", Int J Hematol, 99, pp.635~643 (2014)
- Oshikawa G, "Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome", Pathol Oncol Res, 21, pp.1037~1043 (2015)
- Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes", Blood, 120, pp.2454~2465 (2012)
- Silverman LR, "Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221by the Cancer and Leukemia Group B", J Clin Oncol, 24, pp.3895~3903 (2006)
- Cheson BD, "Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia", Blood, 108, pp.419~425 (2006)
- Vigorito AC, "Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD", Blood, 114, pp.702~708 (2009)
- Silverman LR, "Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes", Cancer, 117, pp.2697~2702 (2011)
- Becker H, "Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt): results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)", Ann Hematol, 94, pp.2003~2013 (2015)
- Musto P, "Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program", Cancer, 116, pp.1485~1494 (2010)
- Lubbert M, "Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS)ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group", J Clin Oncol, 29, pp.1987~1996 (2011)
- Sekeres MA, "How we treat higher-risk myelodysplastic syndromes", Blood, 123, pp.829~836 (2014)
- Lubbert M, "Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group", Ann Hematol, 95, pp.191~199 (2016)
- Brierley CK, "Thrombopoiesis-stimulating agents and myelodysplastic syndromes", Br J Haematol, 169, pp.309~323 (2015)
- Gauthier J, "The role of pre-transplant debulking treatment in patients undergoing allogeneic stem cell transplantation for high-risk myelodysplastic syndrome", Bull Cancer, 102, pp.340~348 (2015)
- Bejar R, "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients", Blood, 124, pp.2705~2712 (2014)
- Itzykson R, "Impact of TET2mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias", Leukemia, 25, pp.1147~1152 (2011)
- Wermke M, "Preparing patients with myelodysplastic syndrome for transplant when is pre-transplant cytoreductive therapy appropriate?", Curr Hematol Malig Rep, 10, pp.329~333 (2015)
- Sohn SK, "Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS", Crit Rev Oncol Hematol, 95, pp.243~250 (2015)
- Oran B, "Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation", Biol Blood Marrow Transplant, 20, pp.1618~1625 (2014)
- Martino M, "Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents", Curr Cancer Drug Targets, 13, pp.661~669 (2013)